FDA Approves New U.S. Labeling for ISENTRESS® (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS ...
Monday, July 1, 2013 5:05 pm EDT "As the care of HIV evolves, ISENTRESS continues to be an important treatment option for adult patients with HIV-1" WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United …